Au(<scp>iii</scp>)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells

Brustolin, Leonardo; Pettenuzzo, Nicolò; Nardon, Chiara; Quarta, Santina; Marchiò, Luciano; Biondi, Barbara; Pontisso, Patrizia; Fregona, Dolores

doi:10.1039/c9dt03036k

“…As mentioned earlier, Au 3 + ions are not stable under physiological conditions and the use of chelating ligands is required. Diverse chelated Au III compounds are under investigation to be used as potential anticancer drugs, including bidentate ligands as dithiolates, [125,126] dithiocarbamates, [127] diamines, [128,129] or diphosphines. [56] Moreover, the use of tri-and tetra-dentated ligands as Schiff bases, [68] pincer ligands, [130] and porphyrins [61] have shown promising results, in some cases uncovering unexpected and diverse mechanisms of action.…”

Section: Gold(iii) Complexesmentioning

confidence: 99%

Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems

Moreno‐Alcántar

¹

,

Picchetti

²

,

Casini

³

2023

View full text Add to dashboard Cite

The discovery of the medicinal properties of gold complexes has fuelled the design and synthesis of new anticancer metallodrugs, which have received special attention due to their unique modes of action. Current research in the development of gold compounds with therapeutic properties is predominantly focused on the molecular design of drug leads with superior pharmacological activities, e.g., by introducing targeting features. Moreover, intensive research aims at improving the physicochemical properties of gold compounds, such as chemical stability and solubility in the physiological environment. In this regard, the encapsulation of gold compounds in nanocarriers or their chemical grafting onto targeted delivery vectors could lead to new nanomedicines that eventually reach clinical applications. Herein, we provide an overview of the state‐of‐the‐art progress of gold anticancer compounds, andmore importantly we thoroughly revise the development of nanoparticle‐based delivery systems for gold chemotherapeutics.

show abstract

“…The use of dithiocarbamate ligands with the addition of additional donor groups such as oxygen and nitrogen contained in amino acids in the synthesis of complex compounds can increase anticancer activity [ 7 - 9 ]. The choice of the amino acid cysteine-tyrosine is generally recognized as the ability to safely deliver cytotoxic units into aggressive cancer cells [ 10 , 11 ]. This compound can also be used as a radio chemotherapy-targeted agent in tumors.…”

Section: Introductionmentioning

confidence: 99%

Investigations of Ni(II)Cysteine-Tyrosine Dithiocarbamate Complex: Synthesis, Characterization, Molecular Docking, Molecular Dynamic, and Anticancer Activity on MCF-7 Breast Cancer Cell Line

Pratiwi,

Raya,

Natsir

et al. 2024

Asian Pac J Cancer Prev

0

View full text Add to dashboard Cite

Objective: Breast cancer ranks second in terms of the highest number of cancer deaths for women worldwide and is one of the leading causes of death from cancer in women. The drug that is often used for chemotherapy is cisplatin. However, cisplatin drugs have a number of problems, including lack of selectivity, unwanted side effects, resistance, and toxicity in the body. In this work, we investigated Ni(II) cysteine-tyrosine dithiocarbamate complex against breast cancer. Methods: Research on the new complex compound Ni(II) cysteine-tyrosine dithiocarbamate have several stages including synthesis, characterization, in-silico and in-vitro testing of MCF-7 cells for anticancer drugs. The synthesis involved reacting cysteine, CS2, KOH and tyrosine with Mn metal. The new complex compound Ni(II) cysteine-tyrosine dithiocarbamate has been synthesized, characterized, and tested in vitro MCF-7 cells for anticancer drugs. Characterization tests such as melting point, conductivity, SEM-EDS, UV Vis, XRD, and FT-IR spectroscopy have been carried out. Result: The synthesis yielded a 60,16%, conversion with a melting point of 216-218 oC and a conductivity value of 0.4 mS/cm. In vitro test results showed morphological changes (apoptosis) in MCF-7 cancer cells starting at a sample concentration of 250 µg/mL and an IC 50 value of 618.40 µg/mL. Molecular docking study of Ni(II) cysteine-tyrosine dithiocarbamate complex identified with 4,4’,4’’-[(2R)-butane-1,1,2-triyl]triphenol - Estrogen α showing active site with acidic residue amino E323, M388, L387, G390 and I389. Hydrophobic and hydrophobic bonds are seen in Ni(II) cysteine-tyrosine dithiocarbamate - Estrogen α has a binding energy of -80.9429 kJ /mol. Conclusion: there were 5 residues responsible for maintaining the ligand binding stable. The compound had significant Hbond contact intensity, however, it was not strong enough to make a significant anticancer effect. Though the synthesized compound shows low bioactivity, this research is expected to give valuable insight into the effect of molecular structure on anticancer activity.

show abstract

Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems

Moreno‐Alcántar

¹

,

Picchetti

²

,

Casini

³

2023

View full text Add to dashboard Cite

The discovery of the medicinal properties of gold complexes has fuelled the design and synthesis of new anticancer metallodrugs, which have received special attention due to their unique modes of action. Current research in the development of gold compounds with therapeutic properties is predominantly focused on the molecular design of drug leads with superior pharmacological activities, e.g., by introducing targeting features. Moreover, intensive research aims at improving the physicochemical properties of gold compounds, such as chemical stability and solubility in the physiological environment. In this regard, the encapsulation of gold compounds in nanocarriers or their chemical grafting onto targeted delivery vectors could lead to new nanomedicines that eventually reach clinical applications. Herein, we provide an overview of the state‐of‐the‐art progress of gold anticancer compounds, andmore importantly we thoroughly revise the development of nanoparticle‐based delivery systems for gold chemotherapeutics.

show abstract

Au(iii)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells

Abstract: This paper deals with the combination of a proline-based moiety with biologically active gold centers in the oxidation states +1 and +3.

Cited by 6 publications

References 50 publications

Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems

Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems

Investigations of Ni(II)Cysteine-Tyrosine Dithiocarbamate Complex: Synthesis, Characterization, Molecular Docking, Molecular Dynamic, and Anticancer Activity on MCF-7 Breast Cancer Cell Line

Gold Complexes in Anticancer Therapy: From New Design Principles to Particle‐Based Delivery Systems

Contact Info

Product

Resources

About